Green tea compound may improve cancer drugs

Conclusion This study developed a new way of packaging and carrying protein drugs by combining them with a green tea extract called Epigallocatechin-3-O-gallate (EGCG), which itself may have anti-cancer properties. They formed a complex between derivatives of EGCG and the protein cancer drug Herceptin. Tests in the laboratory and in mice indicated it might have better anti-cancer properties than non-complexed free Herceptin. This is encouraging research and may lead to improvements in delivery mechanisms for protein drugs further down the line. But this research remains at a very early stage of development. The results from the laboratory and mice studies need to be confirmed by other research groups before the team can consider testing potential treatments in humans. Only then will they be able to assess whether such a drug delivery system could benefit people. These further studies will have to pay special attention to potential side effects of the drugs. Green tea extracts are often the subject of news headlines, often in the very early stages of drug development. Other claims made about green tea include how it can help prevent prostate cancer, reduce stroke risk, boost the ability of the brain, and help ward off Alzheimer's disease. Some people have even gone as far as claiming the beverage is a “"superfood". Many of these claims are not backed by robust evidence, however. Overall, this new nanotechnology might prove useful in many years' t...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Medication Source Type: news

Related Links:

AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Source: St. Michael's Hospital News and Media - Category: Hospital Management Tags: Hospital News Source Type: news
AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Authors: Geis N, Raake P, Kiriakou C, Mereles D, Frankenstein L, Abu-Sharar H, Chorianopoulos E, Katus HA, Bekeredjian R, Pleger ST Abstract BACKGROUND: Incidence of stroke within 30 days after percutaneous mitral valve repair using the MitraClip varies from 0.7% and 2.6% between registries. Standard medical treatment after the MitraClip procedure, in the absence of risk factors requiring antithrombotic therapy such as atrial fibrillation, is dual antiplatelet therapy using aspirin and clopidogrel. ESC/EACTS and ACC/AHA surgical guidelines show a Class IIa indication for temporary antithrombotic therapy after ...
Source: Acta Cardiologica - Category: Cardiology Tags: Acta Cardiol Source Type: research
The drug was previously designated a "breakthrough therapy."
Source: ABC News: Health - Category: Consumer Health News Tags: Health Source Type: news
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory. Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1232-1244 Authors: Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P Abstract Purpose On January 1st, 2018, the ÖGZ (Austrian Society of Cytology) revised its cytological nomenclature to make it more similar to the 2015 Bethesda system...
Source: Geburtshilfe und Frauenheilkunde - Category: OBGYN Tags: Geburtshilfe Frauenheilkd Source Type: research
Authors: Vallianou NG, Tzortzatou-Stathopoulou F Abstract The number of microbes in the human intestine is approximately 1 × 1014, while the number of eukaryotic cells in the human body is around 1 × 1013. As a result of co-evolution of the host mucosal immune system and the microbiota, both have developed multiple mechanisms to maintain homeostasis. Nevertheless, when these mechanisms are disturbed by pathogenic bacteria, which invade this fragile environment, the immune system responds to the microbiota and may support tumour growth in the intestine. Data advocate that the ...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Publication date: Available online 18 January 2019Source: Inorganic Chemistry CommunicationsAuthor(s): Yi-Dong Bin, Yan Yang, Xu-Jian Luo, Hua-Xin ZhangAbstractA novel Pt(II) complex of [PtII(MPP)(OPD)]Cl⋅H2O (MPP-Pt) (OPD = o-phenylenediamine) with 2-(2,5-methoxy-phenyl) imidazo [4,5-f]-[1, 10] phenanthrolin (H-MPP) was synthesized and fully characterized. In MPP-Pt complex, the Pt(II) ion adopts a four-coordinated square planar geometry. MPP-Pt exhibited selective cytotoxicity against human carcinoma (A549), hepatoblastoma (Hep-G2), ovarian (SK-OV-3), cervical (HeLa) and gastric adenocarcinoma (MGC80–3) ce...
Source: Inorganic Chemistry Communications - Category: Chemistry Source Type: research
More News: Alzheimer's | Biology | Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Gastric (Stomach) Cancer | Green Tea | Harvard | Health | Herceptin | Laboratory Medicine | Middle East Health | Nanotechnology | Neurology | Prostate Cancer | Science | Stroke | Study | Tea | Toxicology